SCHEMBL23119175

SCHEMBL23119175

Cc1nc(N2C[C@@H](C)O[C@@H](C)C2)n2c1cnc1ccc(Br)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.39
▸ PIK3CB P42338 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ PRKDC P78527 1/20 0.39
▸ ATR Q13535 1/20 0.39
▸ ATRIP Q8WXE1 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.36
▸ KDM4E B2RXH2 5/20 0.36
▸ GAA P10253 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ TSHR P16473 3/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MAPT P10636 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KMT2A Q03164 3/20 0.33
▸ POLB P06746 2/20 0.33
▸ HTT P42858 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23119274 0.81 ATM (0.44) ATMPIK3CBMTORPRKDCATR
SCHEMBL23093851 0.79 PIK3CB (0.41) ATMPIK3CBMTORPRKDCATR
SCHEMBL23093867 0.79 PRKDC (0.41) ATMPIK3CBMTORPRKDCATR
SCHEMBL29688031 0.76 AOC3 (0.40) ATMPIK3CBMTORPRKDCATR
SCHEMBL23093845 0.76 AOC3 (0.40) ATMPIK3CBMTORPRKDCATR
SCHEMBL29688283 0.75 ATM (0.42) ATMPIK3CBMTORPRKDCATR
SCHEMBL23093827 0.75 ATM (0.42) ATMPIK3CBMTORPRKDCATR
SCHEMBL23119287 0.75 ATM (0.46) ATMPIK3CBMTORPRKDCATR
SCHEMBL23093838 0.75 AOC3 (0.39) ATMPIK3CBMTORPRKDCATR
SCHEMBL23119292 0.75 ATM (0.46) ATMPIK3CBMTORPRKDCATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119215050-A Application of substituted imidazoquinoxaline compound in preparation of anti-cancer drugs 上海瑛派药业有限公司 2024-12-31 — — CN disclosed
CN-119080781-A Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2024-12-06 — — CN disclosed
CN-114787162-B Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2024-09-03 — — CN disclosed
US-20220354859-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-11-10 — — US disclosed
CN-114787162-A Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2022-07-22 — — CN disclosed
EP-4028400-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-07-20 — — EP disclosed
WO-2021047646-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF IMPACT THERAPEUTICS, INC (CN) 2021-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220354859-A1 SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF CHEK2, CHEK1, ATM ATM 3/4885PIK3CB 214/4885MTOR 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback